About Ovensa

Ovensa is a preclinical stage company working to fight inherent therapeutic resistance in complex diseases by generating advanced nanotherapeutics through its proprietary TRIOZAN™ Platform. The company focuses on advancing its lead nanotherapeutic candidate that synergistically improves efficacy of chemotherapy and checkpoint inhibitors in glioblastoma.


Ovensa is seeking for strategic partnerships with companies interested to modulate synergistically the efficacy of their checkpoint inhibitors and/or other immuno-oncology therapies aimed to induce T cell response in glioblastoma and/or other solid tumors through a combination regimen involving our lead candidate. Ovensa is also welcoming collaborative discovery research programs aiming to deliver in the brain biological based therapeutic assets for CNS applications.